March 29, 2011
Mass High Tech
GI Dynamics diabetic device shows positive study results
GI Dynamics Inc., a Lexington medical device firm, has announced results of three studies of its EndoBarrier Gastrointestinal Liner in treating type 2 diabetes and obesity.
The EndoBarrier, inserted in the GI tract endoscopically, was found to improve glycemic control and weight loss, according to a news release from the company. The study involved 17 obese patients using the implanted EndoBarrier for 24 weeks.
The study showed that the EndoBarrier had the same effect as gastric bypass surgery on patients with type 2 diabetes, the release noted. After one year of using the EndoBarrier, patients showed 39 percent absolute weight loss, decreased glucose levels, and normalized levels of insulin, cholesterol, LDL and triglycerides.
The EndoBarrier is commercially available in Europe and South America and is an advanced investigational device in the United States.
Founded in 2003, GI Dynamics is backed by Advanced Technology Ventures, Catalyst Health Ventures, Cutlass Capital, Domain Associates, Johnson & Johnson Development Corp., Medtronic Inc. and Polaris Venture Partners.